Pharmacokinetics of sulbactam-durlobactam in patients with <i>Acinetobacter baumannii</i> ventriculitis: a report of two cases

Two adult patients with ventriculitis due to <i>Acinetobacter baumannii</i> were treated with intravenous sulbactam-durlobactam as a part of a combination regimen. Penetration into the central nervous system was estimated (by cerebrospinal fluid [CSF]/serum area under the curve [AUC] ratios at steady state) for sulbactam (0.47-0.64) and durlobactam (0.27-0.3), respectively. In view of mostly constant CSF concentrations, single CSF levels at steady state may offer a more convenient and clinically applicable approach for monitoring therapy.